Cancer Research The Future of Cancer Research: Science and Patient Impact Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mao, W.
Right arrow Articles by Polakis, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mao, W.
Right arrow Articles by Polakis, P.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Experimental Therapeutics– Biologics
[Cancer Research 64, 781-788, February 1, 2004]
© 2004 American Association for Cancer Research

Review

EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer

Weiguang Mao1, Elizabeth Luis1, Sarajane Ross1, Johnny Silva1, Christine Tan1, Craig Crowley1, Clarissa Chui1, Gretchen Franz1, Peter Senter2, Hartmut Koeppen1 and Paul Polakis1

1 Departments of Molecular Biology, Protein Chemistry, and Molecular Oncology, Genentech, Inc., South San Francisco, California, and 2 Seattle Genetics, Bothell, Washington

Analysis of human colorectal cancer specimens revealed overexpression of the EphB2 receptor tyrosine kinase. Monoclonal antibodies (MAbs) to extracellular sequence of EphB2 were raised and tested for activity against colorectal cancer cells. One of the MAbs, 2H9, effectively blocked the interaction of ephB2 with ephrin ligands and inhibited the resulting autophosphorylation of the receptor. However, this antibody did not affect the proliferation of cancer cells expressing ephB2. Immunocytochemical analysis revealed rapid internalization of the MAb 2H9 on binding ephB2, suggesting that target-dependent cell killing could be achieved with an antibody-drug conjugate. When MAb 2H9 was conjugated to monomethylauristatin E through a cathepsin B-cleavable linker, it specifically killed ephB2-expressing cancer cells in vitro and in vivo. Our results suggest that ephB2 is an attractive target for immunoconjugate cancer therapy.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
C. F. McDonagh, K. M. Kim, E. Turcott, L. L. Brown, L. Westendorf, T. Feist, D. Sussman, I. Stone, M. Anderson, J. Miyamoto, et al.
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Mol. Cancer Ther., September 1, 2008; 7(9): 2913 - 2923.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
M. Lackmann and A. W. Boyd
Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?
Sci. Signal., April 15, 2008; 1(15): re2 - re2.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. E. Chrencik, A. Brooun, M. I. Recht, G. Nicola, L. K. Davis, R. Abagyan, H. Widmer, E. B. Pasquale, and P. Kuhn
Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition
J. Biol. Chem., December 14, 2007; 282(50): 36505 - 36513.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Chen, S. Clark, T. Wong, Y. Chen, Y. Chen, M. S. Dennis, E. Luis, F. Zhong, S. Bheddah, H. Koeppen, et al.
Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models
Cancer Res., May 15, 2007; 67(10): 4924 - 4932.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. J. Pelham, L. Rodgers, I. Hall, R. Lucito, K. C. Q. Nguyen, N. Navin, J. Hicks, D. Mu, S. Powers, M. Wigler, et al.
Identification of alterations in DNA copy number in host stromal cells during tumor progression
PNAS, December 26, 2006; 103(52): 19848 - 19853.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Salvucci, M. de la Luz Sierra, J. A. Martina, P. J. McCormick, and G. Tosato
EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling
Blood, November 1, 2006; 108(9): 2914 - 2922.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nakada, K. L. Drake, S. Nakada, J. A. Niska, and M. E. Berens
Ephrin-B3 Ligand Promotes Glioma Invasion through Activation of Rac1.
Cancer Res., September 1, 2006; 66(17): 8492 - 8500.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
C. F. McDonagh, E. Turcott, L. Westendorf, J. B. Webster, S. C. Alley, K. Kim, J. Andreyka, I. Stone, K. J. Hamblett, J. A. Francisco, et al.
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Protein Eng. Des. Sel., July 1, 2006; 19(7): 299 - 307.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. M. Vihanto, C. Vindis, V. Djonov, D. P. Cerretti, and U. Huynh-Do
Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase
J. Cell Sci., June 1, 2006; 119(11): 2299 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Ma, C. E. Hopf, A. D. Malewicz, G. P. Donovan, P. D. Senter, W. F. Goeckeler, P. J. Maddon, and W. C. Olson
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
Clin. Cancer Res., April 15, 2006; 12(8): 2591 - 2596.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. S. K. Sutherland, R. J. Sanderson, K. A. Gordon, J. Andreyka, C. G. Cerveny, C. Yu, T. S. Lewis, D. L. Meyer, R. F. Zabinski, S. O. Doronina, et al.
Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates
J. Biol. Chem., April 14, 2006; 281(15): 10540 - 10547.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. L. Guo, J. Zhang, S. T. Yuen, W. Y. Tsui, A. S.Y. Chan, C. Ho, J. Ji, S. Y. Leung, and X. Chen
Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours
Carcinogenesis, March 1, 2006; 27(3): 454 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Lugli, H. Spichtin, R. Maurer, M. Mirlacher, J. Kiefer, P. Huusko, D. Azorsa, L. Terracciano, G. Sauter, O.-P Kallioniemi, et al.
EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers
Clin. Cancer Res., September 15, 2005; 11(18): 6450 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein, A. Farmanfarmaian, and T. Minko
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
PNAS, September 6, 2005; 102(36): 12962 - 12967.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Vearing, F.-T. Lee, S. Wimmer-Kleikamp, V. Spirkoska, C. To, C. Stylianou, M. Spanevello, M. Brechbiel, A. W. Boyd, A. M. Scott, et al.
Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents
Cancer Res., August 1, 2005; 65(15): 6745 - 6754.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Nakada, J. A. Niska, N. L. Tran, W. S. McDonough, and M. E. Berens
EphB2/R-Ras Signaling Regulates Glioma Cell Adhesion, Growth, and Invasion
Am. J. Pathol., August 1, 2005; 167(2): 565 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Jubb, F. Zhong, S. Bheddah, H. I. Grabsch, G. D. Frantz, W. Mueller, V. Kavi, P. Quirke, P. Polakis, and H. Koeppen
EphB2 is a Prognostic Factor in Colorectal Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5181 - 5187.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Koolpe, R. Burgess, M. Dail, and E. B. Pasquale
EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity
J. Biol. Chem., April 29, 2005; 280(17): 17301 - 17311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Sanderson, M. A. Hering, S. F. James, M. M.C. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, and A. F. Wahl
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Clin. Cancer Res., January 15, 2005; 11(2): 843 - 852.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Carter, L. Smith, and M. Ryan
Identification and validation of cell surface antigens for antibody targeting in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.